Vetter's €1.5 billion investment focuses on expanding commercial and clinical production, with a new plant in Saarlouis, Germany, creating up to 2,000 jobs. The US expansion prioritizes clinical ...

In a 2026 industry outlook interview, Raj Puri explains balancing speed with the financial and regulatory risks of accelerated drug launches via alignment. Raj Puri, chief commercial officer at ...

Eli Lilly will invest $3.5 billion in a Pennsylvania facility for injectable weight-loss medicines, creating 850 new jobs and starting by 2031.

Vertical integration and securing scarce inputs are becoming strategic priorities due to complex biologics and fragile supply chains. M&A report claims that pharma is now targeting vertical ...

This week's coverage discusses the M&A report, $50B+ investments, automated cell therapy, vaccine approvals, and risks from the US leaving the WHO. In this PharmTech video feature, we highlight the ...

Repertoire Immune Medicines partners with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving $85 ...

Ultimately, the interview underscores a critical transition period for the industry. While tariffs present a unique hurdle ...

Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the ...

Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026 ...

Government shutdowns lead to decreased predictability, causing delays in new submissions and manufacturing changes. Key risk ...

HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, ...

Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...